Volume 9 Supplement 1
Problems of HIV positive tuberculosis patients' health care in Latvia
© Viksna et al; licensee BioMed Central Ltd. 2012
Published: 25 May 2012
The number of patients with HIV/TB alliance has increased recently. There were 1055 TB/HIV cases registered in European Union (6% out of 17 650 TB cases tested for HIV) in 2010, among them 71 in Latvia (9.5% out of all TB cases in 2010, in comparison with 0.5% in 2000). The treatment for TB/HIV cases is provided in Latvia according to WHO recommendations, including DOTS strategy. However the TB treatment results for HIV positive cases are concerning due to increasing resistance to HIV/AIDS drugs and to TB drugs.
The treatment results for 7761 new smear and/or culture positive pulmonary TB cases were analyzed, 234 among them were HIV positive. In HIV/AIDS naive patients in general the resistance is found in 5.3% of cases. In treated patients the resistance to different groups of drugs is detected in 41% of cases: to all -3%, to NRTI – 14%, to NRTI+NNRTI – 9%, to NRTII+PL – 6%, to NNRTI – 6%, to NNRTI+PI – 1%, to PI – 2%. Multidrug resistance (MDR) was diagnosed in 14% of TB cases. Molecular biological, immunofluorescence, bacteriological and bacterioscopic methods were used for detection of initiating agents. The TB treatment results for HIV positive and HIV negative cases from the period 2000-2007 were compared with the results reported in 2010. Data for 2000-2007 was grouped together due to small number of HIV positive cases within the period.
The treatment success for HIV positive cases was lower in both periods (60-61%) in comparison with HIV negative cases (78-76%). The level of MDR TB cases among HIV positive patients was higher (15%) than in HIV negative patients (8%) during the years 2000-2007, but similar in both groups (9-10,6%) in 2010. Despite improvements in HIV/AIDS treatment since 2000, the death rate among HIV positive cases in 2010 was higher (18%) than during the years 2000-2007 (11%).
The resistance to HIV/AIDS drugs is a factor influencing the TB treatment results.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.